Biofrontera Inc. (NASDAQ:BFRI – Get Free Report) was the target of a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 255,272 shares, an increase of 675.7% from the August 15th total of 32,907 shares. Approximately 1.9% of the shares of the stock are sold short. Based on an average trading volume of 674,900 shares, the short-interest ratio is presently 0.4 days.
Institutional Investors Weigh In On Biofrontera
A hedge fund recently raised its position in Biofrontera stock. Geode Capital Management LLC raised its position in Biofrontera Inc. (NASDAQ:BFRI – Free Report) by 54.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,677 shares of the company’s stock after purchasing an additional 23,074 shares during the quarter. Geode Capital Management LLC owned 0.56% of Biofrontera worth $37,000 at the end of the most recent quarter. 10.08% of the stock is owned by hedge funds and other institutional investors.
Biofrontera Price Performance
Biofrontera stock opened at $1.55 on Friday. Biofrontera has a 1 year low of $0.55 and a 1 year high of $1.66. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.08 and a current ratio of 1.18. The firm has a 50 day moving average price of $1.30 and a 200 day moving average price of $1.07. The company has a market cap of $23.02 million, a price-to-earnings ratio of -3.44 and a beta of 0.83.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on BFRI. Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Biofrontera from a “hold” rating to a “buy” rating in a report on Saturday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Biofrontera has a consensus rating of “Hold”.
View Our Latest Stock Report on Biofrontera
About Biofrontera
Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.
The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.
Featured Stories
- Five stocks we like better than Biofrontera
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
